Lancet Diabetes & Endocrinology

Article	Citations
Direct-to-consumer services: improving access to care for people with diabetes and obesity	840
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	740
South Africa to produce insulin for Africa in 2024	708
World Health Assembly ratifies first global diabetes targets	537
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	521
Better testing and labelling of drugs for people with obesity	520
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	477
Anand Hardikar: a scientific nomad searching for the truth	467
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	448
Reassessing driving safety in diabetes	446
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	383
Implications of technology guidelines for low-income and middle-income countries	330
A framework for improving diabetes care in humanitarian emergencies	256
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	239
What's preventing us from curbing the obesity crisis?	216
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	204
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice	189
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity	184
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	179
Artificial intelligence and diabetes: time for action and caution	171
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	171
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	165
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	161
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	159
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	154

Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	144
What does renal failure teach us about our National Health System?	144
Childhood obesity: a growing pandemic	143
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	142
The role of nurses in diabetes care: challenges and opportunities	142
Cardiovascular mortality trends among people with and without diabetes	140
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	137
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X	137
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss	136
A roadmap for integrating mental health and diabetes services	127
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	116
Healthy weight for the next generation's health in China	110
Challenging diabetes stigma starts and ends with all of us	105
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	104
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	103
The uncomfortable truth about kidney disease in type 1 diabetes	103
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	101
The changing character of diabetes complications	101
Jennifer Manne-Goehler: at the crossroads of pandemics	95
The urgent need for a diabetes data rights charter	94
Lebanon: insulin out of reach after subsidies lifted	94
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial	93
Putting wellbeing at the core of diabetes care	90
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England	89
Glycaemic index as part of the diabetes prevention strategy	89
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement	89
The promise and hope of GLP-1 receptor agonists	88
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	88
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	85
Rising diabetes diagnosis in long COVID	84
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	83
Understanding the mechanism of prediabetes remission in young people	83
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	83
CONCEPTT to care: the science of implementation in diabetes care	83
Homing in on the causes of male infertility	82
Women in diabetes research: stepping towards equity	79
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	78
Diabetes: knowing your risk matters	78
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	74
Gender equality: timely and timeless	74
Improving HbA1c levels with advanced hybrid closed-loop therapy	74
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	73
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	71
Is it time to re-assess the development of thyroid function reference ranges?	70
Blood pressure control according to type 2 diabetes status	70
Male hypogonadism: pathogenesis, diagnosis, and management	68
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	68
Hypothalamic obesity: from basic mechanisms to clinical perspectives	67
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	66
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	65

Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?	64
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	64
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	64
The long and winding road to precision diabetology	63
Staging prediabetes and type 2 diabetes: the time to start is now	63
Glucagon, from past to present: a century of intensive research and controversies	62
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019	61
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes	60
Improving support for university students with type 1 diabetes	60
Corrections to Lancet Diabetes Endocrinol 2022; 10: 120–28	59
Central diabetes insipidus from a patient's perspective	58
On the occasion of International Women's Day	58
Chronicling insulin from discovery to crisis	57
Teplizumab approval for type 1 diabetes in the USA	56
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	55
Screening type 1 diabetes and celiac disease by law	55
Diagnosing diabetes in African populations: a twist in the tale	55
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial	55
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	53
Has the WHO Model Essential Medicines List lost its way?	52
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	51
Vitamin D and fractures	51
Embracing multiplicity in global diabetes estimation methods	51
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	50
Embracing community sport to promote global health	50
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	50
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	49
Management of menopause: a view towards prevention	48
Young adult-onset type 2 diabetes heralds a poor prognosis	48
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	47
Automated insulin delivery postpartum: insights from the AiDAPT study extension	47
Methodological considerations in D-health cancer mortality results – Authors' reply	47
How do clinicians integrate oral octreotide into their treatment plan for acromegaly?	46
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care	46
Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia	44
Correction to Lancet Diabetes Endocrinol 2025; 13: 909–10	44
Insulin regimens during type 1 diabetes pregnancy	44
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	44
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050	43
Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia?	43
Technology for type 1 diabetes: what impact will it have?	43
Blood glucose targets in the critically ill: is one size fits all still appropriate?	43
More options for young children with type 1 diabetes	43
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	43
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	42
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	42
Life stage transitions for people with type 1 diabetes	41
MarÍa José Redondo: rethinking type 1 diabetes	41
Disparities in fragility fracture and osteoporosis care in Africa	41
From reproduction to metabolism: FSH as a key modulator in menopause	41
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	40
ORION-3: delivering lipid lowering treatment for longer	40
Enhancing global access to diabetes medicines: policy lessons from the HIV response	40
An inclusive approach to people with disabilities in diabetes care and education	40
Creating diabetes guidelines for the individual not just the illness	39
Viswanathan Mohan: a dynasty of diabetology	39
Is the impact of add on heart failure therapy influenced by background therapy?	39
Impact of higher BMI on cardiometabolic risk: does height matter?	39
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	38
Diabetes and cancer in the age of multimorbidity	38
How clinically relevant is statin-induced diabetes?	38
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	37
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	37
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	37
Redefining obesity: advancing care for better lives	37
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	37
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	37
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	36
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	36
Addressing health and demographic challenges in Japan's ageing society	34
Disease modifying therapies in diabetes and endocrinology	33
Mendelian randomisation and vitamin D: the importance of model assumptions	33
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	33
Risks and burdens of incident diabetes in long COVID: a cohort study	33
Iodine deficiency in Europe: vigilance and action required	33
Data processing in the DMagic cluster randomised controlled trial	32
Diabetes and the WHO Model List of Essential Medicines	32
From prominent corneal nerves to multiple endocrine neoplasia type 2B	31
What's in a decade?	31
Improving type 1 diabetes care globally: the importance of medical education	30

The growing global burden of thyroid cancer overdiagnosis	29
Setmelanotide: new promise for the treatment of hypothalamic obesity?	29
Incretins and the cardiovascular system: bridging digestion with metabolism	28
The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula	28
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	28
Task shifting and task sharing in paediatric type 1 diabetes care: a global survey	28
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	27
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	26
Sleep: a neglected public health issue	26
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	26
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis	25
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	24
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	24
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	24
The potential role for artificial intelligence in fracture risk prediction	24
Sex differences in familial hypercholesterolaemia	24
Osteoporosis in men	24
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	23
Heterogeneity in type 2 diabetes trajectories: informing public health approaches	23
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial	23
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	23
Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study	23
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis	23
Maternal thyroid hypofunction and gestational diabetes risk	22
The double burden of poor diets	22
From research to policy: still a long way to go	21
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial	21
Bariatric surgery in children with obesity and type 2 diabetes	21
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	21
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	21
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	21
Prevention of diabetes mortality at ages younger than 25 years: access to medications and high-quality health care	21
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	20
Sexual dimorphism in COVID-19: potential clinical and public health implications	20
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	20
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	20
Endocrine health in survivors of adult-onset cancer	20
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	20
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?	19
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	19
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	19
The power of resilience	18
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	18
A global plastics treaty to protect endocrine health	18
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	18
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	18
Peripheral CB1 receptor blockade for treatment of obesity	18
Addressing the educational needs of older adults with type 1 diabetes	18
Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden	18
The voices of lived experience in diabetes and endocrinology	17
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality – Authors' reply	17
COVID-19 targets human adrenal glands	17
Does tirzepatide treatment improve skeletal muscle composition?	17
A call for increased involvement of people with obesity and neurodiversity in policy, research, and practice	17
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	16
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies	16
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	16
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	16
Predicting and preventing heart failure in type 2 diabetes	16
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial	16
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	16
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	16
Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium	16
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	16
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	16
Is autonomous cortisol secretion sexually dimorphic?	15
Endpoints for clinical trials in type 1 diabetes drug development	15
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention	15
Access to insulin and diabetes care in the Philippines	15
The evidence for achondroplasia in 1st century AD Italy	15
The actual burden of obesity—accounting for multimorbidity	15
Food additive emulsifiers and risk of type 2 diabetes	15
Diabetes educators: rewriting the narrative	14
The obesity drug craze in Brazil	14
Correction to Lancet Diabetes Endocrinol 2023; 11: 567–77	14
Harmonising terminology for type 1 diabetes: the EDENT1FI lexicon initiative	14
The ISPAD Clinical Practice Consensus Guidelines 2022: how far we have come and the distance still to go	14
Migrant health: a global responsibility	14
Heart failure: now centre-stage in diabetes	14
Alarming rise in young-onset type 2 diabetes	13
Osteoporosis in the USA: prevention and unmet needs	13
Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity	13
Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial	13
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, paralle	13
Causes, prevention, and management of diabetes-related foot ulcers	13
Denosumab in the treatment of osteoporosis associated with chronic kidney disease	13
Vitamin D and acute respiratory infections: a definitive answer?	13
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada	12
Closed-loop systems: a bridge to cell therapy for type 1 diabetes?	12
Bariatric tourism	12
Polycystic ovary syndrome	12
Social learning theories and metabolic health: the centenary of Bandura's birth	12
Melatonin: is it really a cardiovascular wonder pill for shift workers?	12
The enduring effect of the COVID-19 pandemic on diabetes	12
Khalida Ismail: merging diabetes and mental health	12